Clinical Trial Results:
Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib (ME
401) in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma
After Failure of Two or More Prior Systemic Therapies – The TIDAL Study
Summary
|
|
EudraCT number |
2018-002896-17 |
Trial protocol |
GB FR BE AT DE ES IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Jun 2023
|
First version publication date |
11 Jun 2023
|
Other versions |
|
Summary report(s) |
ME-401-003 - Synopsis - OUS |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.